Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Company Performance - Novavax (NVAX) closed at $8.97, reflecting a +2.51% increase from the previous day, outperforming the S&P 500 which had a daily loss of 0.01% [1] - Over the past month, Novavax shares gained 0.92%, while the Medical sector and S&P 500 experienced losses of 1.31% and 0.28% respectively [1] Earnings Expectations - The upcoming earnings report for Novavax is expected to show an EPS of -$0.66, a decline of 29.41% compared to the same quarter last year [2] - Revenue is anticipated to be $78.41 million, indicating an 11.21% decrease from the same quarter of the previous year [2] Full-Year Estimates - Zacks Consensus Estimates project full-year earnings of $1.94 per share and revenue of $1.05 billion, representing year-over-year increases of +257.72% and +54.62% respectively [3] Analyst Forecast Revisions - Recent revisions to analyst forecasts for Novavax are important as they reflect short-term business trends, with positive revisions indicating analysts' confidence in the company's performance [4] Zacks Rank System - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has shown that 1 ranked stocks have yielded an average annual return of +25% since 1988 [6] - Novavax currently holds a Zacks Rank of 3 (Hold), with a 9.04% increase in the Zacks Consensus EPS estimate over the last 30 days [6] Industry Context - Novavax operates within the Medical - Biomedical and Genetics industry, which has a Zacks Industry Rank of 84, placing it in the top 35% of over 250 industries [7] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [7]